| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Division of Medical Oncology, University of Texas Health Science Center at San Antonio, San Antonio, Texas 78284 [D. Y., F. R. M., D. D. V. H.], and Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [T. C. H.]
Insulin-like growth factor (IGF) I is a polypeptide hormone important in normal growth and development. Although IGF-I is a mitogen for many cancer cell lines, previous work has suggested that autocrine production of IGF-I is uncommon in cancers of epithelial origin. In this study, expression of IGF-I, its binding proteins, and its receptor were examined in ovarian cancer cell lines and tissues. Of 10 ovarian cancer cell lines, 3 (OVCAR-3, OVCAR-7, and PEO4) expressed IGF-I mRNA. RNase protection assays using probes derived from IGF-IA, IGF-IB, and alternate exon 1 IGF-I complementary DNAs demonstrated that these cells contained a predominant IGF-I transcript with an alternate first exon. RNA extracted from primary and metastatic ovarian cancer tissues also expressed IGF-I mRNAs (7 of 7) with the alternate first exon. IGF-I protein was detected in OVCAR-3-conditioned media; this activity was secreted in conjunction with several IGF-binding proteins (IGFBPs). IGFBP-2, IGFBP-3, an Mr 24,000 species, and an Mr 30,000 species could also be demonstrated in OVCAR-3. Type I IGF receptor mRNA was found in all 10 of the ovarian cancer cell lines and all 7 of the primary or metastatic ovarian cancer tissues. IGF-I was a mitogen for OVCAR-3, demonstrating the presence of a functional type I IGF receptor. These data show that all the necessary components for an IGF-I-mediated autocrine loop are expressed by ovarian cancer cells.
1 Supported by National Cancer Institute Grant R29 CA52592 and an institional grant (IN-116 K) from the American Cancer Society (D.Y.). D. Y. is a Pew Scholar in the Biomedical Sciences.
2 To whom reprint requests should be addressed, at Division of Medical Oncology, University of Texas Health Science Center at San Antonio, 7703 Floyd Curl Drive, San Antonio, TX 78284.
Received 4/18/91. Accepted 7/17/91.
This article has been cited by other articles:
![]() |
S. Ravikumar, G. Perez-Liz, L. Del Vale, D. R. Soprano, and K. J. Soprano Insulin Receptor Substrate-1 Is an Important Mediator of Ovarian Cancer Cell Growth Suppression by All-trans Retinoic Acid Cancer Res., October 1, 2007; 67(19): 9266 - 9275. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. K. Rowinsky, H. Youssoufian, J. R. Tonra, P. Solomon, D. Burtrum, and D. L. Ludwig IMC-A12, a Human IgG1 Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Clin. Cancer Res., September 15, 2007; 13(18): 5549s - 5555s. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt The Role of the IGF System in Cancer Growth and Metastasis: Overview and Recent Insights Endocr. Rev., February 1, 2007; 28(1): 20 - 47. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. W. Allen, C. Saba, E. A. Armstrong, S.-M. Huang, S. Benavente, D. L. Ludwig, D. J. Hicklin, and P. M. Harari Insulin-like Growth Factor-I Receptor Signaling Blockade Combined with Radiation Cancer Res., February 1, 2007; 67(3): 1155 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Davidson, Z. Zhang, L. Kleinberg, M. Li, V. A. Florenes, T.-L. Wang, and I.-M. Shih Gene expression signatures differentiate ovarian/peritoneal serous carcinoma from diffuse malignant peritoneal mesothelioma. Clin. Cancer Res., October 15, 2006; 12(20): 5944 - 5950. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. L. Adamo, X. Ma, C. L. Ackert-Bicknell, L. R. Donahue, W. G. Beamer, and C. J. Rosen Genetic Increase in Serum Insulin-Like Growth Factor-I (IGF-I) in C3H/HeJ Compared with C57BL/6J Mice Is Associated with Increased Transcription from the IGF-I Exon 2 Promoter Endocrinology, June 1, 2006; 147(6): 2944 - 2955. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Burtrum, Z. Zhu, D. Lu, D. M. Anderson, M. Prewett, D. S. Pereira, R. Bassi, R. Abdullah, A. T. Hooper, H. Koo, et al. A Fully Human Monoclonal Antibody to the Insulin-Like Growth Factor I Receptor Blocks Ligand-Dependent Signaling and Inhibits Human Tumor Growth in Vivo Cancer Res., December 15, 2003; 63(24): 8912 - 8921. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Hoeflich, R. Reisinger, H. Lahm, W. Kiess, W. F. Blum, H. J. Kolb, M. M. Weber, and E. Wolf Insulin-like Growth Factor-binding Protein 2 in Tumorigenesis: Protector or Promoter? Cancer Res., December 1, 2001; 61(24): 8601 - 8610. [Full Text] [PDF] |
||||
![]() |
I. Chatzistamou, A. V. Schally, J. L. Varga, K. Groot, P. Armatis, R. Busto, and G. Halmos Antagonists of Growth Hormone-Releasing Hormone and Somatostatin Analog RC-160 Inhibit the Growth of the OV-1063 Human Epithelial Ovarian Cancer Cell Line Xenografted into Nude Mice J. Clin. Endocrinol. Metab., May 1, 2001; 86(5): 2144 - 2152. [Abstract] [Full Text] |
||||
![]() |
N. Auersperg, A. S. T. Wong, K.-C. Choi, S. K. Kang, and P. C. K. Leung Ovarian Surface Epithelium: Biology, Endocrinology, and Pathology Endocr. Rev., April 1, 2001; 22(2): 255 - 288. [Abstract] [Full Text] |
||||
![]() |
L. Wang and M. L. Adamo Cell Density Influences Insulin-Like Growth Factor I Gene Expression in a Cell Type-Specific Manner Endocrinology, July 1, 2000; 141(7): 2481 - 2489. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. M. Khandwala, I. E. McCutcheon, A. Flyvbjerg, and K. E. Friend The Effects of Insulin-Like Growth Factors on Tumorigenesis and Neoplastic Growth Endocr. Rev., June 1, 2000; 21(3): 215 - 244. [Abstract] [Full Text] |
||||
![]() |
D. Coppola, B. Saunders, L. Fu, W. Mao, and S. V. Nicosia The Insulin-like Growth Factor 1 Receptor Induces Transformation and Tumorigenicity of Ovarian Mesothelial Cells and Down-Regulates Their Fas-Receptor Expression Cancer Res., July 1, 1999; 59(13): 3264 - 3270. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Freier, O Weiss, M Eran, A Flyvbjerg, R Dahan, I Nephesh, T Safra, E Shiloni, and I Raz Expression of the insulin-like growth factors and their receptors in adenocarcinoma of the colon Gut, May 1, 1999; 44(5): 704 - 708. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, J. L. Talamantez, and M. L. Adamo A CACCC Box in the Proximal Exon 2 Promoter of the Rat Insulin-Like Growth Factor I Gene Is Required for Basal Promoter Activity Endocrinology, March 1, 1998; 139(3): 1054 - 1066. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Flyvbjerg, O. Mogensen, B. Mogensen, and O. S. Nielsen Elevated Serum Insulin-Like Growth Factor-Binding Protein 2 (IGFBP-2) and Decreased IGFBP-3 in Epithelial Ovarian Cancer: Correlation with Cancer Antigen 125 and Tumor-Associated Trypsin Inhibitor J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2308 - 2313. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, Y. Yang, and M. L. Adamo Characterization of the Rat Insulin-Like Growth Factor I Gene Promoters and Identification of a Minimal Exon 2 Promoter Endocrinology, April 1, 1997; 138(4): 1528 - 1536. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Du and P. Delafontaine Inhibition of Vascular Smooth Muscle Cell Growth Through Antisense Transcription of a Rat Insulin-Like Growth Factor I Receptor cDNA Circ. Res., June 1, 1995; 76(6): 963 - 972. [Abstract] [Full Text] |
||||
![]() |
A. Berchuck, A. Elbendary, L. Havrilesky, G. C. Rodriguez, and R. C. Bast Pathogenesis of Ovarian Cancers Reproductive Sciences, July 1, 1994; 1(3): 181 - 190. [Abstract] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |